After leaving NVIDIA and Palantir, Stanley Druckenmiller is refocusing his focus. In addition to another AI winner, a pharmaceutical title is also in focus.
• Druckenmiller divests from NVIDIA and Palantir papers
• AI sector still remains promising
• Pharmaceutical sector in view
Profits realized: Druckenmiller divests NVIDIA and Palantir
Star investor Stanley Druckenmiller completely sold his holdings in the two AI flagship companies NVIDIA and Palantir over the last year. He was previously one of the earliest prominent investors to recognize the potential of artificial intelligence (AI): he bought NVIDIA shares in the third quarter of 2022 and made them his largest position at times. Palantir has also been one of his top investments since the beginning of 2021.
While he continues to see the artificial intelligence space as one of the biggest growth drivers of the future, he cautions against stretched valuations, as The Motley Fool explains. NVIDIA had “tripled in size within a year,” explained Druckenmiller and, although he later described his sale as a “big mistake”, he saw the stock as overvalued at the time.
He was similarly critical of Palantir – the stock is now trading at around 280 times expected earnings. After years of enormous price gains, Druckenmiller was looking for new opportunities – even outside the overheated AI sector.
New AI star in the portfolio
However, Druckenmiller’s sales are not a general rejection of the AI sector, but rather a strategic shift, The Motley Fool explains. Instead of investing in overheated stocks, the billionaire expanded his position in a well-known favorite in the second quarter: Microsoft.
For Druckenmiller, Microsoft is the clear beneficiary of the AI boom – especially through the Azure cloud division, which recorded sales growth of 34 percent to over $75 billion in the current year.
Focus on the pharmaceutical sector
The billionaire also massively expanded his position in the Israeli-American pharmaceutical company Teva Pharmaceuticals – more than at any other company in 2025. His family office acquired around 16 million Teva shares worth over $267 million.
Teva is one of the world’s largest manufacturers of generic and branded drugs. Key products include Austedo®, used for movement disorders such as Huntington’s disease, and Ajovy®, a migraine prevention medication. The company is also working on treatments for asthma, cancer, COPD and schizophrenia.
Analysts are also optimistic about the stock: According to The Motley Fool, UBS analyst Ashwani Verma recently raised the price target for Teva and gave the stock a “buy” rating. He expects sales to grow to $6.6 billion by 2030, supported by strong brand business. With a P/E ratio of under 8, the stock is considered attractively valued despite the ongoing turnaround – a solid, defensive investment in the midst of an overheated AI market.
Editorial team finanzen.net
This text is for informational purposes only and does not constitute an investment recommendation. finanzen.net GmbH excludes any claims for recourse.
By the way: Microsoft and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on Microsoft
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Microsoft
The leverage must be between 2 and 20
Advertising
Image sources: Konstantin Savusia / Shutterstock.com, Piotr Swat / Shutterstock.com